Ipamorelin vs Tesamorelin
Research Verdict
Tesamorelin is the stronger research reference for the stated comparison criteria. Tesamorelin: FDA approved (2010) for HIV-associated lipodystrophy, Phase 3 data showing visceral fat reduction (Falutz 2007, 2008).
Quick Answers
Which is better, Ipamorelin or Tesamorelin?
Tesamorelin is the stronger research reference for the stated comparison criteria. Tesamorelin: FDA approved (2010) for HIV-associated lipodystrophy, Phase 3 data showing visceral fat reduction (Falutz 2007, 2008).
What is the key difference between Ipamorelin and Tesamorelin?
Tesamorelin is a GHRH analog (like sermorelin but with a trans-3-hexenoic acid modification for stability); ipamorelin is a GHRP - they stimulate GH through different pituitary receptor mechanisms, making the combination potentially synergistic.
Evidence Comparison
Tesamorelin: FDA approved (2010) for HIV-associated lipodystrophy, Phase 3 data showing visceral fat reduction (Falutz 2007, 2008). Ipamorelin: Phase 2 post-operative ileus only. Tesamorelin has much stronger clinical evidence and regulatory standing.
Evidence Context Favoring Ipamorelin
GHRP-mechanism research requiring selective GH pulsatility without cortisol or prolactin effects.
Evidence Context Favoring Tesamorelin
HIV lipodystrophy, visceral fat reduction, or research requiring an FDA-approved GHRH-class agent with Phase 3 data.
Side-by-Side Snapshot
| Evidence grade | Ipamorelin: Level B Tesamorelin: Level A |
|---|---|
| Research status | Ipamorelin: Phase 2 Tesamorelin: FDA Approved |
| Primary category | Ipamorelin: Growth Hormone Tesamorelin: Growth Hormone |
| Cited studies | Ipamorelin: 3 Tesamorelin: 3 |